Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1987 Apr 1;136(7):701–707.

The role of oral acyclovir in the management of genital herpes simplex.

S L Sacks
PMCID: PMC1491931  PMID: 3548933

Abstract

Oral acyclovir is an antiviral nucleoside analogue that has recently been released in Canada for use in selected patients with genital infections by the herpes simplex virus. First episodes of genital herpes should be treated with oral acyclovir as soon as the diagnosis is considered. Most people with recurrent genital herpes do not require systemic drug therapy. Selected patients with severe or long-lasting recurrences, recurrences associated with long prodromal periods (greater than 12 to 24 hours) or systemic complications such as erythema multiforme and eczema herpeticum may receive measurable benefit from treatment at the onset of symptoms. In most patients frequently recurrent disease can be suppressed with long-term therapy. Since long-term safety beyond 1 year has not been established, suppressive therapy should be stopped at least once per year to reassess the recurrence pattern. Acyclovir has not been adequately tested for safety in pregnancy and should not be prescribed for pregnant women unless the potential benefits outweigh the risks. Careful attention to disease severity, accurate diagnosis and exclusion of other causes of genital lesions will ensure that the drug is used only when beneficial.

Full text

PDF
701

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bean B., Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis. 1985 Feb;151(2):362–365. doi: 10.1093/infdis/151.2.362. [DOI] [PubMed] [Google Scholar]
  2. Bryson Y. J., Dillon M., Lovett M., Acuna G., Taylor S., Cherry J. D., Johnson B. L., Wiesmeier E., Growdon W., Creagh-Kirk T. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983 Apr 21;308(16):916–921. doi: 10.1056/NEJM198304213081602. [DOI] [PubMed] [Google Scholar]
  3. Bryson Y., Dillon M., Lovett M., Bernstein D., Garratty E., Sayre J. Treatment of first episode genital HSV with oral acyclovir: long term follow-up of recurrences. A preliminary report. Scand J Infect Dis Suppl. 1985;47:70–75. [PubMed] [Google Scholar]
  4. Caplan L. R., Kleeman F. J., Berg S. Urinary retention probably secondary to herpes genitalis. N Engl J Med. 1977 Oct 27;297(17):920–921. doi: 10.1056/NEJM197710272971708. [DOI] [PubMed] [Google Scholar]
  5. Corey L., Adams H. G., Brown Z. A., Holmes K. K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983 Jun;98(6):958–972. doi: 10.7326/0003-4819-98-6-958. [DOI] [PubMed] [Google Scholar]
  6. Corey L., Mindel A., Fife K. H., Sutherland S., Benedetti J., Adler M. W. Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. Sex Transm Dis. 1985 Oct-Dec;12(4):215–218. doi: 10.1097/00007435-198510000-00009. [DOI] [PubMed] [Google Scholar]
  7. Corey L., Nahmias A. J., Guinan M. E., Benedetti J. K., Critchlow C. W., Holmes K. K. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med. 1982 Jun 3;306(22):1313–1319. doi: 10.1056/NEJM198206033062201. [DOI] [PubMed] [Google Scholar]
  8. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Elion G. B. Mechanism of action and selectivity of acyclovir. Am J Med. 1982 Jul 20;73(1A):7–13. doi: 10.1016/0002-9343(82)90055-9. [DOI] [PubMed] [Google Scholar]
  10. Field H. J., Bell S. E., Elion G. B., Nash A. A., Wildy P. Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother. 1979 Apr;15(4):554–561. doi: 10.1128/aac.15.4.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Furman P. A., St Clair M. H., Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem. 1984 Aug 10;259(15):9575–9579. [PubMed] [Google Scholar]
  12. Goldberg L. H., Sperber J. Erythema multiforme due to herpes simplex: treatment with oral acyclovir. South Med J. 1986 Jun;79(6):757–759. doi: 10.1097/00007611-198606000-00027. [DOI] [PubMed] [Google Scholar]
  13. Goodell S. E., Quinn T. C., Mkrtichian E., Schuffler M. D., Holmes K. K., Corey L. Herpes simplex virus proctitis in homosexual men. Clinical, sigmoidoscopic, and histopathological features. N Engl J Med. 1983 Apr 14;308(15):868–871. doi: 10.1056/NEJM198304143081503. [DOI] [PubMed] [Google Scholar]
  14. Halsos A. M., Salo O. P., Lassus A., Tjøtta E. A., Hovi T., Gabrielsen B. O., Fiddian A. P. Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study. Acta Derm Venereol. 1985;65(1):59–63. [PubMed] [Google Scholar]
  15. Klastersky J., Cappel R., Snoeck J. M., Flament J., Thiry L. Ascending myelitis in association with herpes-simplex virus. N Engl J Med. 1972 Jul 27;287(4):182–184. doi: 10.1056/NEJM197207272870411. [DOI] [PubMed] [Google Scholar]
  16. Laskin O. L. Acyclovir and suppression of frequently recurring herpetic whitlow. Ann Intern Med. 1985 Apr;102(4):494–495. doi: 10.7326/0003-4819-102-4-494. [DOI] [PubMed] [Google Scholar]
  17. Laskin O. L., Longstreth J. A., Whelton A., Rocco L., Lietman P. S., Krasny H. C., Keeney R. E. Acyclovir kinetics in end-stage renal disease. Clin Pharmacol Ther. 1982 May;31(5):594–601. doi: 10.1038/clpt.1982.83. [DOI] [PubMed] [Google Scholar]
  18. Lehrman S. N., Douglas J. M., Corey L., Barry D. W. Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med. 1986 Jun;104(6):786–790. doi: 10.7326/0003-4819-104-6-786. [DOI] [PubMed] [Google Scholar]
  19. Lemak M. A., Duvic M., Bean S. F. Oral acyclovir for the prevention of herpes-associated erythema multiforme. J Am Acad Dermatol. 1986 Jul;15(1):50–54. doi: 10.1016/s0190-9622(86)70141-2. [DOI] [PubMed] [Google Scholar]
  20. Mertz G. J., Critchlow C. W., Benedetti J., Reichman R. C., Dolin R., Connor J., Redfield D. C., Savoia M. C., Richman D. D., Tyrrell D. L. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA. 1984 Sep 7;252(9):1147–1151. [PubMed] [Google Scholar]
  21. Mindel A., Weller I. V., Faherty A., Sutherland S., Hindley D., Fiddian A. P., Adler M. W. Prophylactic oral acyclovir in recurrent genital herpes. Lancet. 1984 Jul 14;2(8394):57–59. doi: 10.1016/s0140-6736(84)90237-x. [DOI] [PubMed] [Google Scholar]
  22. Nilsen A. E., Aasen T., Halsos A. M., Kinge B. R., Tjøtta E. A., Wikström K., Fiddian A. P. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982 Sep 11;2(8298):571–573. doi: 10.1016/s0140-6736(82)90658-4. [DOI] [PubMed] [Google Scholar]
  23. Reichman R. C., Badger G. J., Mertz G. J., Corey L., Richman D. D., Connor J. D., Redfield D., Savoia M. C., Oxman M. N., Bryson Y. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA. 1984 Apr 27;251(16):2103–2107. [PubMed] [Google Scholar]
  24. Richards D. M., Carmine A. A., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1983 Nov;26(5):378–438. doi: 10.2165/00003495-198326050-00002. [DOI] [PubMed] [Google Scholar]
  25. Rooney J. F., Felser J. M., Ostrove J. M., Straus S. E. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med. 1986 Jun 12;314(24):1561–1564. doi: 10.1056/NEJM198606123142407. [DOI] [PubMed] [Google Scholar]
  26. Ruhnek-Forsbeck M., Sandström E., Andersson B., Eriksson G., Hersle K., Lövhagen G. B., Mobacken H., Hillström L., Svensson L. Treatment of recurrent genital herpes simplex infections with oral acyclovir. J Antimicrob Chemother. 1985 Nov;16(5):621–628. doi: 10.1093/jac/16.5.621. [DOI] [PubMed] [Google Scholar]
  27. Sacks S. L. Frequency and duration of patient-observed recurrent genital herpes simplex virus infection: characterization of the nonlesional prodrome. J Infect Dis. 1984 Dec;150(6):873–877. doi: 10.1093/infdis/150.6.873. [DOI] [PubMed] [Google Scholar]
  28. Seale L., Jones C. J., Kathpalia S., Jackson G. G., Mozes M., Maddux M. S., Packham D. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA. 1985 Dec 27;254(24):3435–3438. [PubMed] [Google Scholar]
  29. Straus S. E., Takiff H. E., Seidlin M., Bachrach S., Lininger L., DiGiovanna J. J., Western K. A., Smith H. A., Lehrman S. N., Creagh-Kirk T. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med. 1984 Jun 14;310(24):1545–1550. doi: 10.1056/NEJM198406143102401. [DOI] [PubMed] [Google Scholar]
  30. Teh C. Z., Sacks S. L. Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2. Antimicrob Agents Chemother. 1983 May;23(5):637–640. doi: 10.1128/aac.23.5.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Thin R. N., Jeffries D. J., Taylor P. K., Ayra O. P., Rodin P., Yeo J., Fiddian A. P. Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial. J Antimicrob Chemother. 1985 Aug;16(2):219–226. doi: 10.1093/jac/16.2.219. [DOI] [PubMed] [Google Scholar]
  32. Wade J. C., Meyers J. D. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med. 1983 Jun;98(6):921–925. doi: 10.7326/0003-4819-98-6-921. [DOI] [PubMed] [Google Scholar]
  33. Yamamoto H., Walz M. A., Notkins A. L. Viral-specific thymidine kinase in sensory ganglia of mice infected with herpes simplex virus. Virology. 1977 Feb;76(2):866–869. doi: 10.1016/0042-6822(77)90267-7. [DOI] [PubMed] [Google Scholar]
  34. de Miranda P., Blum M. R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):29–37. doi: 10.1093/jac/12.suppl_b.29. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES